Methicillin resistant Staphylococcus aureus infection, unspecified site
ICD-10 A49.02 is a billable code used to indicate a diagnosis of methicillin resistant staphylococcus aureus infection, unspecified site.
Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that is resistant to many antibiotics, including methicillin. It can cause a range of infections, from skin and soft tissue infections to more severe infections such as pneumonia, bloodstream infections, and surgical site infections. In immunocompromised patients, MRSA poses a significant risk due to their weakened immune systems, which can lead to opportunistic infections. These patients may include those undergoing chemotherapy, organ transplant recipients, or individuals with chronic diseases. Diagnosing MRSA infections can be challenging, as symptoms may mimic other infections, and laboratory confirmation is often required. Cultures from the site of infection are essential for accurate diagnosis, but in some cases, the infection may be present without clear clinical signs. The unspecified site designation indicates that the infection location is not clearly defined, which can complicate treatment and management strategies. Proper coding is crucial for appropriate reimbursement and tracking of infection rates, especially in healthcare settings where MRSA is a concern.
Detailed clinical notes on the patient's history, laboratory results, and treatment plans.
Patients presenting with skin infections, pneumonia, or post-surgical infections.
Ensure that MRSA is confirmed through culture and sensitivity testing.
Comprehensive records of the patient's cancer treatment and any immunocompromised status.
Cancer patients developing infections during chemotherapy or after surgery.
Document the patient's neutrophil count and any prophylactic measures taken.
Used when obtaining cultures to confirm MRSA infection.
Document the source of the culture and the clinical indication for testing.
Infectious disease specialists may require additional details on the patient's history.
Coding A49.02 is crucial for tracking MRSA infections, which are associated with higher morbidity and healthcare costs. Accurate coding ensures appropriate treatment protocols and resource allocation.
